Attenuated respiratory syncytial virus vaccine compositions

US5882651A · kind A · utility

Assignees

• The United States of America · US
• Amerimas Home Products, Inc. · US

Inventors

• Brian R. Murphy · Bethesda, US
• Robert M. Chanock · Bethesda, US
• James E. Crowe, Jr. · Nashville, US
• Mark Connors · Bethesda, US
• Kuo-Hom L. Hsu · Fort Washington, US
• Alan R. Davis · Plainwell, US
• Michael D. Lubeck · Glenmoore, US
• Bernard H. Selling · Via Enrico Fermi, US

Key dates

• Filing date: May 30, 1995
• Grant date: Mar 16, 1999
• Expiry date: May 30, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.